298 related articles for article (PubMed ID: 32016808)
21. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
22. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
[TBL] [Abstract][Full Text] [Related]
23. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma.
Rao SN; Zafereo M; Dadu R; Busaidy NL; Hess K; Cote GJ; Williams MD; William WN; Sandulache V; Gross N; Gunn GB; Lu C; Ferrarotto R; Lai SY; Cabanillas ME
Thyroid; 2017 May; 27(5):672-681. PubMed ID: 28068873
[TBL] [Abstract][Full Text] [Related]
24. Anaplastic thyroid carcinomas incidentally found on postoperative pathological examination.
Yoshida A; Sugino K; Sugitani I; Miyauchi A
World J Surg; 2014 Sep; 38(9):2311-6. PubMed ID: 24687351
[TBL] [Abstract][Full Text] [Related]
25. Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012.
Baek SK; Lee MC; Hah JH; Ahn SH; Son YI; Rho YS; Chung PS; Lee YS; Koo BS; Jung KY; Lee BJ
Head Neck; 2017 Jan; 39(1):133-139. PubMed ID: 27534388
[TBL] [Abstract][Full Text] [Related]
26. Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid Cancer.
Zhang L; Ren Z; Su Z; Liu Y; Yang T; Cao M; Jiang Y; Tang Y; Chen H; Zhang W; Gong R; Wei T; Peng Y; Liu B; Zhang W; Yang L; Hu Y; Li Z; Zhu J; Xu H; Shu Y; Luo H
J Clin Endocrinol Metab; 2021 Mar; 106(4):988-998. PubMed ID: 33428730
[TBL] [Abstract][Full Text] [Related]
27. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.
Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA
Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827
[TBL] [Abstract][Full Text] [Related]
28. Genomic Landscape of poorly Differentiated and Anaplastic Thyroid Carcinoma.
Xu B; Ghossein R
Endocr Pathol; 2016 Sep; 27(3):205-12. PubMed ID: 27372303
[TBL] [Abstract][Full Text] [Related]
29. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
30. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
31. Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer.
Roche AM; Fedewa SA; Shi LL; Chen AY
Cancer; 2018 Apr; 124(8):1780-1790. PubMed ID: 29409119
[TBL] [Abstract][Full Text] [Related]
32. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
33. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
Raue F; Frank-Raue K
Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
[TBL] [Abstract][Full Text] [Related]
34. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
[No Abstract] [Full Text] [Related]
35. Anaplastic thyroid carcinoma with chondrosarcomatous differentiation: a case report.
Liu J; Cui N; Ding W; Dong X; Chen X; Jiang J; Liu Y
Diagn Pathol; 2020 Jul; 15(1):89. PubMed ID: 32693811
[TBL] [Abstract][Full Text] [Related]
36. Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer: A case report.
Besic N; Vidergar-Kralj B; Zaletel K; Grasic-Kuhar C
Medicine (Baltimore); 2021 Jun; 100(25):e26384. PubMed ID: 34160415
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic thyroid carcinoma: a 25-year single-institution experience.
Mohebati A; Dilorenzo M; Palmer F; Patel SG; Pfister D; Lee N; Tuttle RM; Shaha AR; Shah JP; Ganly I
Ann Surg Oncol; 2014 May; 21(5):1665-70. PubMed ID: 24554064
[TBL] [Abstract][Full Text] [Related]
38. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe.
Barbaro D; Lapi P; Viacava P; Torregrossa L
BMJ Case Rep; 2020 Dec; 13(12):. PubMed ID: 33370973
[TBL] [Abstract][Full Text] [Related]
39. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
Jin A; Xu J; Wang Y
Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
[TBL] [Abstract][Full Text] [Related]
40. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
Deeken-Draisey A; Yang GY; Gao J; Alexiev BA
Hum Pathol; 2018 Dec; 82():140-148. PubMed ID: 30075157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]